Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months - 20 U.S. Jurisdictions, September 18, 2022-April 1, 2023.
Johnson AG, Linde L, Payne AB, Ali AR, Aden V, Armstrong B, Armstrong B, Auche S, Bayoumi NS, Bennett S, Boulton R, Chang C, Collingwood A, Cueto K, Davidson SL, Du Y, Fleischauer A, Force V, Frank D, Hamilton R, Harame K, Harrington P, Hicks L, Hodis JD, Hoskins M, Jones A, Kanishka F, Kaur R, Kirkendall S, Khan SI, Klioueva A, Link-Gelles R, Lyons S, Mansfield J, Markelz A, Masarik J 3rd, Mendoza E, Morris K, Omoike E, Paritala S, Patel K, Pike M, Pompa XP, Praetorius K, Rammouni N, Razzaghi H, Riggs A, Shi M, Sigalo N, Stanislawski E, Tilakaratne BP, Turner KA, Wiedeman C, Silk BJ, Scobie HM. Johnson AG, et al. Among authors: shi m. MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):667-669. doi: 10.15585/mmwr.mm7224a6. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37319029 Free PMC article. No abstract available.
COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
Johnson AG, Linde L, Ali AR, DeSantis A, Shi M, Adam C, Armstrong B, Armstrong B, Asbell M, Auche S, Bayoumi NS, Bingay B, Chasse M, Christofferson S, Cima M, Cueto K, Cunningham S, Delgadillo J, Dorabawila V, Drenzek C, Dupervil B, Durant T, Fleischauer A, Hamilton R, Harrington P, Hicks L, Hodis JD, Hoefer D, Horrocks S, Hoskins M, Husain S, Ingram LA, Jara A, Jones A, Kanishka FNU, Kaur R, Khan SI, Kirkendall S, Lauro P, Lyons S, Mansfield J, Markelz A, Masarik J 3rd, McCormick D, Mendoza E, Morris KJ, Omoike E, Patel K, Pike MA, Pilishvili T, Praetorius K, Reed IG, Severson RL, Sigalo N, Stanislawski E, Stich S, Tilakaratne BP, Turner KA, Wiedeman C, Zaldivar A, Silk BJ, Scobie HM. Johnson AG, et al. Among authors: shi m. MMWR Morb Mortal Wkly Rep. 2023 Feb 10;72(6):145-152. doi: 10.15585/mmwr.mm7206a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36757865 Free PMC article.
Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.
Ji H, Zhao X, Chen X, Fang H, Gao H, Wei G, Zhang M, Kuang H, Yang B, Cai X, Su Y, Piao C, Zhao S, Li L, Sun W, Xu T, Xu Q, Fan Y, Ye J, Yao C, Shang M, Song G, Chen L, Zheng Q, Xiao X, Yan L, Lian F, Tong X, Jia Z; FOCUS Trial Committees and Investigators. Ji H, et al. JAMA Intern Med. 2024 Jun 3. doi: 10.1001/jamainternmed.2024.1190. Online ahead of print. JAMA Intern Med. 2024. PMID: 38829648
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J. Liu X, et al. Among authors: shi m. Lancet. 2024 May 30:S0140-6736(24)00594-4. doi: 10.1016/S0140-6736(24)00594-4. Online ahead of print. Lancet. 2024. PMID: 38824941
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Zhou F, Qin Y, Yang L, Mao W, Li Q, Dai W, Li W, Wang S, Tang Y, Ma D, Yin X, Deng Y, Yuan Y, Li M, Hu W, Chen D, Li G, Liu Q, Tan P, Fan S, Shi M, Su W, Xu RH. Wang F, et al. Among authors: shi m. Nat Med. 2024 Jun 1. doi: 10.1038/s41591-024-02989-6. Online ahead of print. Nat Med. 2024. PMID: 38824242
7,485 results